Jeong JK, Szabo G, Raso GM, Meli R, Diano S. Deletion of prolyl carboxypeptidase attenuates the metabolic effects of diet-induced obesity. Am J Physiol Endocrinol Metab 302: E1502-E1510, 2012. First published March 27, 2012 doi:10.1152/ajpendo.00544.2011.-␣-Melanocyte-stimulating hormone (␣-MSH) is a critical regulator of energy metabolism. Prolyl carboxypeptidase (PRCP) is an enzyme responsible for its degradation and inactivation. PRCP-null mice (PRCP gt/gt ) showed elevated levels of brain ␣-MSH, reduced food intake, and a leaner phenotype compared with wild-type controls. In addition, they were protected against diet-induced obesity. Here, we show that PRCP gt/gt animals have improved metabolic parameters compared with wild-type controls under a standard chow diet (SD) as well as on a high-fat diet (HFD). Similarly to when they are exposed to SD, PRCP gt/gt mice exposed to HFD for 13 wk showed a leaner phenotype due to decreased fat mass, increased energy expenditure, and locomotor activity. They also showed improved insulin sensitivity and glucose tolerance compared with WT controls and a significant reduction in fasting glucose levels. These improvements occured before changes in body weight and composition were evident, suggesting that the beneficial effect of PRCP ablation is independent of the adiposity levels. In support of a reduced gluconeogenesis, liver PEPCK and G-6-Pase mRNA levels were reduced significantly in PRCP gt/gt compared with WT mice. A significant decrease in liver weight and hepatic triglycerides were also observed in PRCP gt/gt compared with WT mice. Altogether, our data suggest that PRCP is an important regulator of energy and glucose homeostasis since its deletion significantly improves metabolic parameters in mice exposed to both SD and HFD.
A PRECISE CONTROL OF CALORIC INTAKE and energy expenditure is fundamental for the balance of energy homeostasis. In the mammalian brain, a product of the proopiomelanocortin (POMC) gene, ␣-melanocyte-stimulating hormone (␣-MSH) plays a central role in detecting, integrating, and responding to a range of central and peripheral inputs relating to energy metabolism (1, 4, 13, 14, 20) . The use of genetically altered mouse models has shown the importance of ␣-MSH in the regulation of a broad range of metabolic parameters (9, 17) . Mice with ablation of the POMC gene are obese, whereas mice overexpressing ␣-MSH in the brain showed protection against diet-induced obesity with improved glucose homeostasis.
We have reported recently a molecular mechanism that is responsible for the inactivation and degradation of ␣-MSH (21) . Prolylcarboxypeptidase (PRCP) is a serine protease that cleaves the last amino acid at the COOH terminus of small peptides if proline is the penultimate amino acid. We have shown previously that PRCP is expressed in the lateral hypothalamus, where PRCP-expressing neurons target with their axons the paraventricular nucleus of the hypothalamus, a site where ␣-MSH is released from POMC terminals to stimulate melanocortin 4 receptor-expressing neurons. PRCP is also expressed in the dorsomedial nucleus of the hypothalamus where melanocortin 4 receptor-expressing neurons are located (21) . We have found that animals with PRCP ablation (PRCP gt/gt ) have elevated levels of ␣-MSH in the hypothalamus, decreased food intake, body weight, and fat mass, and increased energy expenditure compared with their wild-type (WT) controls (8, 21) . Moreover, they are protected from diet-induced obesity (21) .
To further characterize the metabolic responses to standard and high-fat diets, we analyzed several metabolic parameters in PRCP-null mice and compared them with the WT controls.
MATERIALS AND METHODS
Animals. All animal work in these studies was approved by the Yale University Institutional Animal Care and Use Committee. Male mice were studied to Յ16 wk of age. All mice studied were on a C57Bl6 background, that being the transgenic mice back-crossed for Ն10 generations. Animals were housed under a 12:12-h light-dark cycle at 25°C and had a free access to either a standard chow diet (SD; Harlan Teklad no. 2018, 18% calories from fat) or a 45% high-fat diet (HFD; Harlan Teklad no. 93075) for Յ13 wk from weaning.
Metabolic chamber recording and body composition. Animals for each group (n ϭ 8 for both PRCP gt/gt and WT on HFD for 13 wk and n ϭ 5 for both PRCP gt/gt and WT on HFD for 7-8 wk) were acclimated in metabolic chambers (TSE System-Core Metabolic Phenotyping Center, Yale University) for 4 days before the start of the recordings. Mice were continuously recorded for 3 days, with the following measurements taken every 30 min: water intake, food intake, ambularoty activity (in the x-and z-axes), and gas exchange (O 2 and CO2; The TSE LabMaster System). CO2 production (V CO2) and energy expenditure were calculated according to the manufacturer's guidelines (PhenoMaster Software, TSE System). The respiratory exchange rate was estimated by calculating the ratio of V CO2 to oxygen consumption (V O2 Glucose and insulin tolerance tests. Glucose tolerance test was performed in 16-to 17-h-fasted animals. After the level of blood glucose was determined, fasted animals were injected intraperitoneally with 20% glucose (10 ml/kg; DeltaSelect) in saline. Blood glucose levels were then monitored at 15, 30, 60, and 120 min from the injection.
Insulin tolerance test was performed with mice fed ad libitum. After determination of basal blood glucose levels, each animal received an intraperitoneal injection of insulin, 0.75 U/kg (Actrapid; Novo Nordisk). Blood glucose levels were then measured at 15, 30, 60, and 120 min after insulin injection.
Statistical analysis. Two-way ANOVA was used to determine the effect of the genotype and diet with the Prism 4.0 software (GraphPad Software, San Diego, CA). For repeated-measures analysis, ANOVA was used when values over different times were analyzed. Significant effects were evaluated (followed) with Fisher's protected least significant difference post hoc test with Bonferroni's correction. When only two groups were analyzed, statistical significance was determined by an unpaired Student t-test. A value of P Ͻ 0.05 was considered statistically significant. All data are shown as means Ϯ SE unless stated otherwise.
RESULTS
Body weight, composition, and energy expenditure. We have shown previously that PRCP gt/gt mice on SD as well as on HFD have a lower body weight compared with WT mice exposed to the same diet (8, 21) . In addition, most recently, we have shown that PRCP gt/gt mice have lower percentages of body fat and increased percentages of lean mass and overall higher energy expenditure when exposed to SD (8) . To assess whether these differences were maintained when exposed to HFD, we measured body weight, body composition, and energy metabolism in PRCP gt/gt and WT mice exposed to HFD. From the beginning of the HFD at weanning, a significant difference in body weight was found at 9 wk of HFD exposure ; n ϭ 4 each, P ϭ 0.96; Fig. 2F ).
Function of PRCP
gt/gt on adipose tissue. To assess the contribution of the brown adipose tissue in the metabolic phenotype of PRCP gt/gt mice, we next analyzed UCP1 mRNA expression levels in animals on HFD for 13 wk (Fig. 3) . UCP1 mRNA levels were significantly higher in PRCP gt/gt compared with WT when animals were exposed to the standard chow diet (0.9 Ϯ 0.04 in WT and 1.9 Ϯ 0.34 in PRCP gt/gt ; n ϭ 4 each, P ϭ 0.03). However, when exposed to HFD, no differences in UCP1 mRNA levels were found (1.9 Ϯ 0.2 in WT and 1.6 Ϯ 0.2 in PRCP gt/gt ; n ϭ 5 each, P ϭ 0.4; Fig. 3 ). Circulating hormone levels. Blood leptin levels were significantly lower in PRCP gt/gt mice compared with those of WT controls on SD as well as 13-wk HFD. On SD, leptin levels in WT and PRCP gt/gt were 15.1 Ϯ 3.2 and 4.7 Ϯ 0.9 ng/ml, respectively (n ϭ 13 and 11, respectively, P ϭ 0.008; Fig. 4A WT mice (10.6 Ϯ 0.6 g/ml; n ϭ 6, P ϭ 0.03; Fig. 4B ). However, no difference in adiponectin levels were observed when the mice were exposed to HFD (8.8 Ϯ 1.3 g/ml in WT and 9.7 Ϯ 1.5 g/ml in PRCP gt/gt mice; n ϭ 6; Fig. 4B ). No differences in active ghrelin levels were found between the two groups under either diet condition (0.20 Ϯ 0.06 pg/ml in WT on SD vs. 0.31 Ϯ 0.05 in PRCP gt/gt on SD, n ϭ 5 and 4, respectively, P ϭ 0.2; 0.07 Ϯ 0.01 pg/ml in WT on HFD vs. 0.05 Ϯ 0.009 pg/ml in PRCP gt/gt on HFD, n ϭ 5 and 4 respectively, P ϭ 0.3; Fig. 4C ). Anyway, HFD significantly reduced active ghrelin in both groups of animals compared with that observed under the SD diet. Also, no difference in total ghrelin levels was observed under the SD diet (0.17 Ϯ 0.03 ng/ml in WT mice and 0.18 Ϯ 0.04 ng/ml in PRCP gt/gt mice, n ϭ 5 and 4, respectively, P ϭ 0.8; Fig. 4D ).
However, on HFD, PRCP gt/gt mice had statistically higher total ghrelin levels (0.17 Ϯ 0.01 ng/ml; n ϭ 4) compared with those of WT animals (0.11 Ϯ 0.005 ng/ml; n ϭ 5, P ϭ 0.002; Fig. 4D ).
Glucose and fatty acid homeostasis. Intraperitoneal glucose and insulin tolerance tests were performed to compare glucose metabolism in PRCP gt/gt mice and WT controls (Fig. 5, A-D) . Fasting glucose levels were significantly lower in PRCP gt/gt mice compared with WT controls when they were exposed to both SD and a 13-wk HFD (time 0; Fig. 5, A and C) . On both diets, glucose tolerance was improved significantly in PRCP gt/gt mice compared with that of WT controls (Fig. 5, A and C) . The area under the glucose response curve was reduced in PRCP gt/gt mice on SD (15%) and 13-wk HFD (25%) compared with WT controls. We then tested insulin tolerance by systemic injection of insulin in fed animals and found that insulin sensitivity was also improved in PRCP gt/gt mice on SD as well as on 13-wk HFD (Fig. 5, B and D) .
To test whether the improvement of glucose and insulin tolerance was due to the difference in adiposity between PRCP gt/gt and WT mice, we analyzed fat mass, glucose tolerance test, and insulin tolerance test in mice exposed to HFD for 8 wk, a time point in which body weight between PRCP 5F ) and lean mass (69.40 Ϯ 2.92% in WT and 71.60 Ϯ 0.84% in PRCP gt/gt mice, P ϭ 0.51; Fig. 5G ) between WT and PRCP gt/gt mice. Similarly to mice exposed to SD and HFD for 13 wk, PRCP gt/gt mice on HFD for 7-8 wk showed a significant decrease in fasting glucose levels and improvement in glucose tolerance test (area under the curve was decreased by 28%) and insulin tolerance test compared with WT mice exposed to HFD for 7-8 wk (Fig. 5, H and I) .
Since PRCP gt/gt mice on SD showed low glucose levels, we measured fasting insulin levels. PRCP gt/gt mice showed significantly lower levels of insulin (0.25 Ϯ 0.03 ng/ml, n ϭ 6) compared with those of WT controls (0.49 Ϯ 0.03 ng/ml, n ϭ 3, P ϭ 0.003; Fig. 6A ). However, in the fed state, no differences in insulin levels were found between WT and PRCP gt/gt mice on SD. WT exposed to 13 wk of HFD showed a significant increase in circulating insulin levels (2.76 Ϯ 0.51 ng/ml) compared with WT and PRCP gt/gt exposed to SD (0.77 Ϯ 0.13 and 0.67 Ϯ 0.09 gt/gt mice showed lower serum leptin levels than the WT controls when exposed to either SD or HFD. B: adiponectin levels were found reduced in PRCP gt/gt mice compared with their WT controls when exposed to SD; no difference was observed in adiponectin levels in mice exposed to HFD. C: HFD reduced active ghrelin levels in WT and PRCP gt/gt mice significantly. However, whereas HFD reduced total ghrelin levels in WT mice significantly, no decrease in total ghrelin levels was observed in PRCP gt/gt mice on HFD compared with PRCP gt/gt mice on SD. *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001. ng/ml, respectively, P Ͻ 0.01; Fig. 6B ) and PRCP gt/gt on HFD for 13 wk (1.55 Ϯ 0.14 ng/ml, P Ͻ 0.05; Fig. 6B ).
Nonesterified fatty acid (NEFA) levels were not different between WT and PRCP gt/gt mice exposed to SD (0.62 Ϯ 0.03 in WT and 0.75 Ϯ 0.08 in PRCP gt/gt , n ϭ 7 each, P ϭ 0.08; Fig. 6C ).
However, 13-wk HFD PRCP gt/gt mice showed lower levels of circulating NEFA (0.32 Ϯ 0.05 meq/l, n ϭ 7) compared with WT controls (0.71 Ϯ 0.08 meq/l, n ϭ 7, P ϭ 0.001; Fig. 6C ).
HFD for 13 wk induced an increase in triglyceride levels in both WT and PRCP gt/gt mice (Fig. 6D) . However, no differences . A and C: both PRCP gt/gt experimental groups showed significantly lower fasting glucose levels compared with their WT control groups. B and D: increased insulin sensitivity was found in PRCP gt/gt mice when exposed to SD and 13-wk HFD. E-G: no difference in body weight (E), %fat (F), or lean mass (G) between WT and PRCP gt/gt mice exposed to HFD for 7-8 wk. When glucose and insulin tolerance tests were performed in these mice, a significant difference in glucose tolerance (H) and insulin sensitivity (I) was noticed between WT and PRCP gt/gt mice, suggesting that the differences in glucose levels observed in SD and 13-wk HFD were not due to changes in adiposity levels.
in triglyceride levels were found between WT and PRCP gt/gt mice when exposed to either SD or 13-wk HFD (68.44 Ϯ 4.73 mg/dl in WT on SD and 79.45 Ϯ 12.75 mg/dl in PRCP gt/gt on SD, n ϭ 8 in both groups, P ϭ 0.43; 109.7 Ϯ 5.33 mg/dl in WT on HFD and 107.0 Ϯ 3.20 mg/dl in PRCP gt/gt on HFD, n ϭ 11 and 20, respectively, P ϭ 0.64; Fig. 6D ).
Liver weight, hepatic lipid accumulation, and gluconeogenesis. No difference in liver weight was found in mice under SD (1.35 Ϯ 0.11 g in WT, n ϭ 7; 1.27 Ϯ 0.06 g in PRCP gt/gt mice, n ϭ 10, P Ͼ0.05; Fig. 7A ). Although liver weight in 7-wk HFD PRCP gt/gt mice was lower (1.08 Ϯ 0.07 g, n ϭ 4) than that of 7-wk HFD WT mice (1.47 Ϯ 0.15 g in WT, n ϭ 4), it was not statistically significant. However, at 13 wk of HFD, a significantly lower liver weight was found in PRCP gt/gt mice (1.31 Ϯ 0.09 g, n ϭ 10) compared with WT controls (1.97 Ϯ 0.15 g, n ϭ 10, P Ͻ 0.01; Fig. 7A ). Hepatic trygliceride levels were significantly lower in PRCP gt/gt mice on SD as well as on HFD for 13 wk. On SD, WT mice had trygliceride levels of 77.3 Ϯ 9.1 mg/dl, whereas PRCP gt/gt mice had 49.9 Ϯ 1.9 mg/dl (n ϭ 9 in both groups, P ϭ 0.01). On HFD for 13 wk, trygliceride levels in WT mice were 294.9 Ϯ 45.2 mg/dl, whereas in PRCP gt/gt mice they were 163.0 Ϯ 16.6 mg/dl (n ϭ 8 and 9, respectively, P ϭ 0.011). Histological analysis of hepatic tissue showed an increase in lipid accumulation specifically in the liver of WT mice exposed to 13 wk of HFD (Fig. 7F ) compared with PRCP gt/gt mice on HFD for 13 wk (Fig.  7E) . No lipid accumulation was observed in the liver of PRCP gt/gt mice on HFD for either 7 (Fig. 7C) or 13 wk (Fig. 7E ) or in WT mice on HFD for 7 wk (Fig. 7D) .
As fasting glucose levels were decreased and the insulin sensitivity was increased in PRCP gt/gt animals, we then compared the mRNA expression levels by real-time PCR of Pepck and G6pase, genes that are involved in liver gluconeogenesis.
No differences in Pepck mRNA levels were observed between all PRCP gt/gt or all WT experimental groups. However, each PRCP gt/gt experimental group showed reduced Pepck mRNA levels compared with those of their corresponding WT control groups (1.2 Ϯ 0.12 in WT and 0.82 Ϯ 0.02 in PRCP gt/gt on SD, n ϭ 9 and 4, respectively, P Ͻ0.05; 1.11 Ϯ 0.22 in WT and 0.84 Ϯ 0.002 in PRCP gt/gt on HFD for 7 wk, n ϭ 4 and 3, respectively, P Ͼ 0.05; 1.3 Ϯ 0.09 in WT and 0.5 Ϯ 0.09 in PRCP gt/gt on HFD for 13 wk, n ϭ 5 and 4, respectively, P Ͻ 0.05; Fig. 7G ), although the difference was not statistically significant in 7-wk HFD mice. G6pase mRNA levels in WT mice were greater when mice were exposed to SD showing decreased levels during the exposure of HFD, reaching a significantly lower level only at 13 wk of HFD (1.0 Ϯ 0.14 in WT on SD, 0.79 Ϯ 0.11 in WT on 7-wk HFD, and 0.34 Ϯ 0.08 in WT on 13-wk HFD; n ϭ 5, 4, and 4, respectively, P Ͻ 0.01). However, no changes in G6pase mRNA levels were observed between the experimental groups of PRCP gt/gt animals (0.47 Ϯ 0.09 on SD, 0.47 Ϯ 0.09 in 7-wk HFD, and 0.26 Ϯ 0.09 in 13-wk HFD; n ϭ 5, 4, and 3, respectively, P Ͼ 0.5; Fig. 7G ).
DISCUSSION
We have shown that mice lacking PRCP are resistant to the development of obesity and adiposity induced by HFD due to reduced food intake (21) and increased energy expenditure (8) . We have also found that deletion of PRCP is associated with improved insulin sensitivity and hyperglycemia induced by the HFD. Furthermore, PRCP-deficient mice are protected against HFD-induced liver steatosis. Liver weight was lower in PRCP gt/gt mice compared with WT controls, with a concomitant reduction in hepatic lipid accumulation and triglyceride content. In addition, the results on the decreased levels of liver Pepck and G6Pase, important genes involved in liver gluconeogenesis, are also consistent with the reduced circulating glucose levels found in PRCP gt/gt mice compared with WT controls when exposed to HFD. More importantly, the improvements in glucose tolerance, insulin sensitivity, and liver gluconeogenesis observed between WT and PRCP gt/gt mice were found already at 7-8 wk-HFD, the time point at which WT and PRCP gt/gt mice showed no difference in body weight and fat mass deposition, an indication that PRCP deletion has beneficial effects on glucose metabolism independent of adiposity. PRCP is one of the serine proteases that cleave the last amino acid at the COOH-terminal end of short peptides that contain proline as the penultimate amino acid. We have shown previously that this enzyme, by degrading it, is an important regulator of ␣-MSH produced by hypothalamic arcuate neurons (21 F) . Note the increase in lipid accumulation in the 13-wk HFD WT mouse (F) compared with the 13-wk HFD PRCP gt/gt mouse (E). G and H: results from the real-time PCR for liver phosphoenolpyruvate carboxykinase (PEPCK; G) and glucose-6-phosphatase (G-6-Pase; H) in WT and PRCP gt/gt mice exposed to SD and HFD for 7 and 13 wk. *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001. Bar scale in F (for C-F) represents 50 m.
be, at least in part, attributed to the increased levels of ␣-MSH. In agreement with this, previous reports studying ␣-MSH overexpression (9, 10, 11, 17) showed similar phenotype and resistance against the development of obesity and diabetes that we observed in PRCP gt/gt mice. Specifically, the studies by Lee et al. (9) and Savontaus et al. (17) have reported that mice overexpressing ␣-MSH are protected from diet-induced obesity, showing increased energy expenditure and improved glucose metabolism. Furthermore, these mice, similarly to our PRCP gt/gt mice, present reduced liver weight and triglyceride content and are protected against liver steatosis. The mechanism by which PRCP deletion prevents liver steatosis is unknown. Several reports have suggested that PRCP, which is expressed in a variety of peripheral organs, plays roles in hypertension, immune response, and angiogenesis (2, 7, 16, 18, 22) . Thus, we cannot exclude the possibility that the phenotype observed in the liver of these mice is due to its direct effect on other substrates of PRCP in the liver and not via the ␣-MSH signaling in the central nervous system. On the other hand, data have shown that hypothalamic ␣-MSH, via its effect on the sympathetic nervous system, plays an important role controlling hepatic gluconeogenesis as well as lipid accumulation in the liver (3, 5, 12) . In support of that, POMC-deficient mice show liver steatosis (6, 19, 23) .
Our studies also show that deletion of PRCP has an impact on glucose metabolism and insulin sensitivity, which was independent of fat mass. PRCP gt/gt mice showed reduced fasting glucose levels when exposed to both SD and HFD for 7-8 or 13 wk. Analysis of the area under the glucose response curve showed the improvement in glucose metabolism in PRCP gt/gt vs. WT mice fed on SD and both high-fat diets. This is consistent with previous reports studying ␣-MSH-overexpressed animals (9) as well as chronically intracerebroventricularly ␣-MSH-infused mice (15) . In addition, insulin sensitivity was also increased in PRCP gt/gt mice on all diets compared with their WT controls. Insulin levels were significantly lower in fasted PRCP gt/gt compared with those of WT mice on SD. No differences in insulin levels were observed in the fed state on a regular chow diet; however, 13-wk HFD fed PRCP gt/gt mice had lower insulin levels. Furthermore, we also found that hepatic gluconeogenesis was decreased in PRCP gt/gt mice compared with WT controls under all diets. Whether the improvement in glucose metabolism, like the prevention of liver steatosis in PRCP gt/gt mice, is centrally mediated or not remains to be elucidated.
Finally, the increased energy expenditure observed in PRCP gt/gt mice cannot be explained only by the increased locomotor activity. Energy expenditure in PRCP gt/gt mice was found to be higher during both the light and dark cycles. When locomotor activity was analyzed, we found that it was elevated only in the dark phase but not during the light phase, an indication that the metabolic phenotype is not dependent on the changes in locomotor activity. In support of this, no changes in locomotor activity during either the light or dark phases were observed in PRCP gt/gt mice exposed to a standard chow diet (8) . In conclusion, our data show that deletion of PRCP induced a reduction of body weight gain, fat mass accumulation, liver steatosis, and improvement in glucose metabolism when mice were exposed to high-fat feeding that was independent of adiposity. Future studies will address whether the deletion of PRCP induces these metabolic improvements via central mechanisms, i.e., higher levels of hypothalamic ␣-MSH, or by acting on other substrates directly in peripheral tissues.
